UPC — Universe Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual income statement for Universe Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.

	2021 September 30th	R2022 September 30th	R2023 September 30th	2024 September 30th	2025 September 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	20-F	20-F	20-F	20-F	20-F
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	48	40.1	32.3	23	17.9
Cost of Revenue
Gross Profit	25.3	21.9	10.3	6.07	6.3
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	34.4	47.2	36.3	31	21.3
Operating Profit	13.6	-7.02	-3.97	-8.02	-3.4
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	13.7	-7.09	-4.33	-8.12	-3.67
Provision for Income Taxes
Net Income After Taxes	11.3	-7.91	-6.58	-8.73	-3.67
Net Income Before Extraordinary Items
Net Income	11.3	-7.91	-6.58	-8.73	-3.67
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	11.3	-7.91	-6.58	-8.73	-3.67
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2,147	-52,369	-43,569	-25,086	-7.01